Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology.

Abstract : BACKGROUND: Aggressive fibromatosis (AF) is a rare fibroblastic proliferative disease with a locally aggressive behavior and no distant metastasis, characterized by driver mutations in CTNNB1 or the APC gene. When progressive and/or symptomatic AF is not amenable to local management, a variety of medical treatments may be efficient, including imatinib mesylate. The phase II "Desminib trial" included 40 patients with AF to evaluate the toxicity and efficacy of imatinib resulting in a 65% tumor control rate at 1 year. We investigated a potential predictive value of KIT exon 10 M541L variant (KITL541) on this prospective series. METHODS: DNA was extracted in sufficient quantity from 33 patients included in the Desminib trial. The detection of KITL541 was performed by Competitive Allele-Specific Taqman® PCR technology. Chi-2 analyses were performed to search for a correlation between KIT status and tumor response. Progression free (PFS) and overall survival (OS) were compared by log-rank test after Kaplan-Meier analysis. RESULTS: In 6 out of 33 cases (18%), the technique failed to determine the mutational status; 5 patients (19%) harboured KITL541 and 22 patients (81%) were classified as KIT wild type. Compared with total cohort, KITL541 frequency did not distinguish between different clinical characteristics. In the KITL541 and the KITWT subgroups, the tumor control rate at 1 year was 100% and 68%, respectively (p = 0.316). The median PFS of patients harboring KITL541 or not is 29.9 and 24.5 months, respectively (p = 0.616), and the median OS is not reached, in any of the groups. CONCLUSION: Our results do not support a predictive effect of KITL541 on the efficacy of imatinib for patients with AF.
Type de document :
Article dans une revue
BMC Cancer, BioMed Central, 2013, pp.632
Liste complète des métadonnées

Littérature citée [26 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-01097447
Contributeur : Christine Dupuis <>
Soumis le : vendredi 19 décembre 2014 - 16:22:20
Dernière modification le : vendredi 23 mars 2018 - 16:43:00
Document(s) archivé(s) le : lundi 23 mars 2015 - 18:29:24

Fichier

1471-2407-14-632.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

  • HAL Id : inserm-01097447, version 1
  • PUBMED : 25174682

Collections

Citation

Armelle Dufresne, Laurent Alberti, Mehdi Brahmi, Sarah Kabani, Héloïse Philippon, et al.. Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology.. BMC Cancer, BioMed Central, 2013, pp.632. 〈inserm-01097447〉

Partager

Métriques

Consultations de la notice

114

Téléchargements de fichiers

89